Mammogen and Brilliantly Combine Forces to Advance Community Efforts for Breast Cancer Previvors and Survivors

Eric Kristiansen • Oct 14, 2021

Female-led women’s health companies announce comprehensive partnership designed to empower breast cancer community

ALISO VIEJO, Calif. & PROVIDENCE, R.I.--(BUSINESS WIRE)--Brilliantly and Mammogen, Inc., two female-led women’s health companies centered around breakthrough technologies designed to solve unmet clinical needs associated with breast cancer, announce a comprehensive partnership expected to improve quality of care for the breast cancer community, both inside and outside of the physician’s office.


The collaboration, which will equip breast cancer previvors and survivors with the tools they need to live empowered lives, is an intentional step towards each company’s commitment to advancing every aspect of women’s health, beyond traditional product-related decisions.


“Over my nearly twenty years in the diagnostics industry, it has always baffled me that companies never invest time or resources to empower the communities that they serve,” said Elizabeth Cormier-May, CEO of Mammogen. “Whether you’re at a higher risk of developing breast cancer based on genetics or family history, newly diagnosed, or past your five-year mark, there’s no shortage of mental, emotional and physical anguish associated with this disease. At Mammogen, we work tirelessly to innovate around the clinical and the personal experience, not only because it makes great business sense; but, most importantly, because it is the right thing to do. We know that end-to-end care is good but creating an end-to-never-end community is far more powerful, and our partnership with Brilliantly brings us a step closer to fulfilling that mission.”


The comprehensive collaboration will first include an exclusive book project which will be a collection of short stories, interviews and creative writing pieces representing hundreds of voices that address everything from talking about hereditary risk with children to sexual dysfunction to career changes.

“For many of us, the aftermath of surgical intervention and treatment has simply been called ‘the new normal’, yet it doesn’t feel normal at all,” stated Kristen Carbone, Founder and CEO of Brilliantly and breast cancer previvor. “How can we feel normal again? Where do we even start? The issues faced by this community are so multifaceted, I struggle to think of even a single part of everyday life that isn’t impacted in some way by an experience with breast cancer,” continued Carbone.


The second initiative is a corrective exercise program that will include various workout modalities to help regain strength and mobility safely for women who’ve had breast surgery and/or treatment. Specific exercise routines for breast cancer patients, survivors, and previvors have been proven to improve quality of life as well as decrease mortality.1 This collaboration between Mammogen and Brilliantly will ensure that all women have access to appropriate exercise routines throughout their journeys.


Both initiatives, while currently underway, will officially kick off in early 2022, upon successfully securing necessary sponsorship.

About Mammogen

Mammogen is a female-led biotechnology company focused on meaningfully improving the detection, diagnosis and treatment of women’s health-related diseases, and creating an end-to-never-end community for women around the world. Mammogen is centered around its proprietary genTRUTM liquid biopsy platform. The company’s flagship genTRU-breastTM program leverages novel messenger RNA (mRNA) technology to non-invasively detect and diagnose breast cancer. The genTRUTM offering is positioned to unlock regular and reliable screening for millions of women around the world and eliminate many negative, invasive biopsy procedures. The company’s proprietary multi-gene expression signature for breast cancer detection has been extensively validated in blood, as well as saliva, and has shown statistical significance towards providing measurable improvement upon current standards of care. Mammogen’s product pipeline consists of an array of non-invasive prognostics and diagnostics for additional diseases that affect some-, mostly-, or only-women. For more information visit www.mammogen.bio.

About Brilliantly

Brilliantly helps women with the transition from confronting breast cancer to embracing life through innovative products, thoughtful content, and relevant services. The company has recently released their flagship technology, Brilliantly Warm, the first-ever wearable designed specifically for women who have had breast reconstruction surgery. For more information visit www.brilliantly.co.


  1. JNCI J Natl Cancer Inst, 2021, Vol. 113, No. 1
02 Dec, 2023
Groundbreaking data unveiled in San Antonio: CLIA validated genTRU-breast assay achieves >99% sensitivity in stage I breast cancer
02 Dec, 2023
272 | "Changing Lives Through Early Disease Detection" with Marty Keiser from IVBH Studio
16 Nov, 2023
World's First Early Detection Blood Test to Unlock Stage I Diagnosis of Breast Cancer
Show More
02 Dec, 2023
Groundbreaking data unveiled in San Antonio: CLIA validated genTRU-breast assay achieves >99% sensitivity in stage I breast cancer
02 Dec, 2023
272 | "Changing Lives Through Early Disease Detection" with Marty Keiser from IVBH Studio
16 Nov, 2023
World's First Early Detection Blood Test to Unlock Stage I Diagnosis of Breast Cancer
By Eric Kristiansen 04 Jun, 2023
IVBH's novel RNA approach to early detection demonstrates strong sensitivity and specificity for early lung cancer detection, in a large, predominantly early-stage, independent validation cohort
By Marty Keiser 22 Mar, 2023
A decade in the making, AI is suddenly everything, everywhere, all at once. In this article I outline three major themes emerging in the current environment. 1. Industrialization. We have officially entered the industrialization era of AI. With the most complex technical foundation already having been laid, success is no longer about the quality of your code, but rather the quality of your prompts. Any person with the right idea, the right focus, and the right prompts, can now solve any problem, in any industry, regardless of their background, socioeconomic status or geography. The floodgates for innovation have officially been opened. 2. Business disruption. Big missions no longer require big teams, big infrastructure, or big budgets. In fact, in the age of abundance, these things are detractors from the mission. Regime change is underway and small, nimble, multi-disciplinary teams who leverage big data and generalized AI tools in a highly specialized way should not be underestimated or undervalued. Size is no longer an advantage, it’s an Achilles heel. 3. People disruption. AI has reached a point where it can now scale humans. The net effect of this is a devaluing of humans without AI, and a devaluing of AI without humans. The two can no longer be treated as mutually exclusive. Humans who fully embrace AI with intention and purpose will win, and they will win big. (The humans who do this most effectively within this decade will be the winners for the next century.)
By Eric Kristiansen 17 Mar, 2023
"Marty Keiser, an accomplished entrepreneur and finance professional, shares his wealth of knowledge and experience in growing and scaling a successful business. From navigating the transition into the science industry (from the finance world), key lessons learned in building a strong and effective team, the challenges faced during growth, and the importance of preserving company culture, Marty sheds light on topics that any entrepreneur or leader can benefit from. He also offers practical insights on defining core values, using those values to guide the hiring process, and identifying the right individuals for your teams. All valuable information for those seeking to grow their own business or improve their leadership within their organization. Marty is also sharing practical resources for listeners!"
By Eric Kristiansen 10 Jan, 2023
R.E.D. campaign to solidify IVBH's leadership position within noninvasive early detection after achieving >90% sensitivity in stage I disease detection in expanded data across 5,000+ case-control subjects
By Eric Kristiansen 10 Jan, 2023
Elizabeth Cormier-May, CEO of Mammogen, Inc., and Dragonfly Data Ventures, Partner and CCO of IV BioHoldings, joins SGH Corp. board of directors to provide expertise and strategy to the Company’s medical arm
By Eric Kristiansen 23 Nov, 2022
Experts say lung cancer screening is an important and easy diagnostic test. Weedezign/Getty Images
By Eric Kristiansen 28 Jun, 2022
This multi-year partnership solidifies IV BioHoldings as an AI-powered organization and will further accelerate the company’s clinical and commercial efforts to transform the paradigm of precision health by detecting, diagnosing and treating patients as individuals, at scale.
More Posts
Share by: